Recently, psychotherapist training for a psychedelic clinical trial that is being led by Beckley Psytech began. This comes as interest in psychedelic substances and the properties and benefits they possess increases in America as well as the United Kingdom.
Beckley Psytech specializes in addressing psychiatric and neurological disorders through new applications for psychedelic drugs. The pioneering phase 2 clinical trial will explore 5-MeO-DMT assisted psychotherapy in the management of treatment-resistant depression.
Psychedelic-assisted psychotherapy refers to the therapeutic process entailing the administration of a psychedelic drug alongside traditional talk-therapy sessions. Prior clinical trials have demonstrated that psychedelic-assisted psychotherapy improves clinical symptoms of various disorders and promotes positive and lasting changes in some patients.
Beckley Psytech CEO Cosmo Feilding Mellen stated that the start of the training program was an important step in the development of an ecosystem that supported the shift in how psychiatric and neurological conditions were treated. The training program is being conducted in partnership with an expertise-driven education platform known as Fluence, which provides professional training in psychedelic therapy for psychotherapists, psychiatrists and social workers, among other healthcare practitioners.
Cofounder of Fluence Dr. Elizabeth Nielson stated that seeing clinicians being involved in and learning Beckley’s therapeutic protocol and approach so they could be well equipped to offer psychedelic-assisted psychotherapy to study participants was encouraging.
Data shows that only about 65% of patients suffering from depression respond to antidepressants, with some of those whose treatments are ineffective exhibiting treatment-resistant symptoms, which is often accompanied by difficulties in occupational and social function, suicidal thoughts and a decline in their physical health. Roughly 30% of patients suffering from treatment-resistant depression don’t respond to any form of treatment.
Beckley Psytech’s objective is to develop a holistic system that will facilitate the delivery of the best care to patients around the globe through a partnership with leading researchers and psychiatrists.
Initial aspects of the training project will include interactive, online, self-taught modules, which will be followed by in-person, live training sessions hosted by San Diego’s Kadima Neuropsychiatry Institute. Director of the Kadima Neuropsychiatry Institute Dr. David Feifel stated that facilitating the training demonstrated the institute’s desire to develop a deeper collaborative relationship with Beckley and ensure the success of this important and exciting project.
This comprehensive program aspires to be the catalyst for significant change among individuals suffering from serious mental health conditions. Beckley Psytech plans to train at least 80 psychotherapists over the next year.
As more of these studies increase society’s understanding of psychedelics and their potential health effects, a lot more companies, such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF), are likely to invest in therapeutic psychedelic product development and patients will be the net beneficiaries of these efforts.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork
